Provention Bio, Inc. Common Stock
PRVB
PRVB was delisted on the 26th of April, 2023.
11 hedge funds and large institutions have $1.13M invested in Provention Bio, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
22% more funds holding
Funds holding: 9 → 11 (+2)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
67% less capital invested
Capital invested by funds: $3.42M → $1.13M (-$2.29M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$163K |
| 2 |
Lido Advisors
Los Angeles,
California
|
+$77K |
| 3 |
AIM
Alambic Investment Management
Belvedere,
California
|
+$47.4K |
| 4 |
BlackRock
New York
|
+$15.7K |
| 5 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
+$4.17K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$652K |
| 2 |
DIM
DC Investments Management
Mclean,
Virginia
|
-$164K |
| 3 |
HighTower Advisors
Chicago,
Illinois
|
-$141K |
| 4 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$45K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$11K |
PRVB Hedge Fund Activity: Q4 2018 in Review
11 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Provention Bio, Inc. Common Stock (PRVB) for Q4 2018, worth a combined $1.13M — down 67% from $3.42M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PRVB positions and 4 closed out — a net gain of 2 holders — while 2 added to existing stakes and 3 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $163K. The largest seller was Vanguard Group, cutting an estimated $652K.
- 11 institutional investors held Provention Bio, Inc. Common Stock (PRVB) as of Q4 2018, up from 9 in Q3 2018.
- Funds reported $1.13M of Provention Bio, Inc. Common Stock stock for Q4 2018, down 67% quarter-over-quarter.
- 6 funds opened new Provention Bio, Inc. Common Stock positions in Q4 2018 and 4 closed out, a net change of +2 holders.
- The largest Provention Bio, Inc. Common Stock buyer in Q4 2018 was Point72 Asset Management, an estimated $163K added.
- The largest Provention Bio, Inc. Common Stock seller in Q4 2018 was Vanguard Group, an estimated $652K sold.
Based on aggregated 13F filings for Q4 2018.